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A 2-day meeting was held by members of the UK Quantitative Systems Pharmacology Network (<http://www.qsp-uk.
net/>) in November 2018 on the topic of Translational Challenges in Oncology. Participants from a wide range of 
backgrounds were invited to discuss current and emerging modeling applications in nonclinical and clinical drug 
development, and to identify areas for improvement. This resulting perspective explores opportunities for impactful 
quantitative pharmacology approaches. Four key themes arose from the presentations and discussions that were 
held, leading to the following recommendations:
• Evaluate the predictivity and reproducibility of animal cancer models through precompetitive collaboration.
• Apply mechanism of action (MoA) based mechanistic models derived from nonclinical data to clinical trial data.
• Apply MoA reflective models across trial data sets to more robustly quantify the natural history of disease and 
response to differing interventions.
• Quantify more robustly the dose and concentration dependence of adverse events through mathematical model-
ling techniques and modified trial design.
There is a growing worldwide population of patients with newly 
diagnosed cancer, 12.7  million in 20081 rising to 17  million in 
2018,2 with a consequent rise in cancer mortality. Thus, there is 
an existing and increasing need for cancer therapies. Estimates of 
the research and development (R&D) cost of a new drug are also 
increasing, with the latest estimate of pre-tax capitalized cost set 
in the order of $2.6 billion per approval.3 Although the most re-
cent estimated total oncology market size was US $123.8 billion in 
2018,4 the cost of failure is considerable as well. The data in ref. 3 
suggest that across therapy areas the capitalized cost per program 
failing in phase III is of the order of $1.2 billion. Clearly there is a 
need to improve efficiency in oncology drug R&D to avoid expos-
ing patients to ineffective treatments and the loss of capital that 
could be spent on other valuable research programs. The largest 
bottleneck in the delivery of new drugs is still in phase II, with 
success rates of merely 36%. This indicates that one of the major 
hurdles is the lack of translatability of the therapeutic index hy-
pothesis, formulated in drug discovery, into the clinical setting. 
Improvement of translational tools to support the decision-making 
process from discovery to development could significantly reduce 
attrition and drug development costs. The purpose of this paper 
is, therefore, to describe the challenges currently faced within the 
field of translational oncology, and to propose recommendations 
on best practices and opportunities for modeling to address these.
The working definition of “translation” extends from nonclin-
ical lead optimization to late development phases. In addition, 
the definition of “translation” is, here, geared toward supporting 
quantitative decision making. Despite a robust and diverse suite 
of in vivo models and successful mathematical models to describe 
tumor growth and treatment effect, examples where these have led 
to successful translational signals are still sparse. Several challenges 
remain, which can be summarized as:
1. Limited understanding of nonclinical in vivo translation into 
clinical activity.
2. Inconsistency in the use of nonclinical in vivo models and 
associated modeling methodologies for decision-making in 
R&D.
3. Inconsistencies and caveats of clinical trial design and practices, 
often leading to poor exploration of dose/concentration-range 
and exposure-response relationships.
4. Disparity in the use and awareness of available mathematical 
modeling tools (e.g., spatial structure considerations, mechani-
cal environment, mode-of-action modeling, etc.).
The following sections describe these challenges in detail and 
provide recommendations for improvement in this field moving 
forward.
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NONCLINICAL IN VIVO TUMOR MODELS USED IN ONCOLOGY
Animal models are important tools for drug discovery, extending 
from target evaluation and validation through to characterization 
of the pharmacology and pharmacodynamics (PDs) of a novel 
therapeutic candidate drug. For targeted therapies, in vitro and in 
vivo tools are routinely used to characterize and quantify the phar-
macology of new drug candidates, with some successful examples 
of quantitative translation to the clinic.5–8 For the emergent field 
of immuno-oncology (IO), animal models are often essential to 
fully explore the drug target biology, given the complexities asso-
ciated with the modulation of the immune system, which cannot 
be faithfully recapitulated using reductionist in vitro systems. 
Given the huge numbers of potential clinical combinations that 
could be explored, nonclinical in vivo models, in concert with 
in vitro systems, can also be used to evaluate combination ap-
proaches. Therefore, data generated in these models can influence 
go/no go decisions for a drug target/molecule in nonclinical devel-
opment and influence the strategy for evaluation in patients. In 
consequence, it is critical that the data generated in these models 
are translationally relevant.
Transplantable xenograft models of cancer allow the study 
of tumor tissues of human origin using a living, but immuno- 
compromised rodent as a host. There is a wide variety of well- 
characterized human cell lines available that can be grown in vivo, 
thus offering a varied menu of cell line-derived xenograft (CDX) 
models with which to study a specific disease setting. Another 
specific type of xenograft model is the patient-derived xenograft 
(PDX), in which primary patient tumor fragments are transplanted 
into mice without the need to establish cell lines. PDX models have 
experienced an extraordinary development in the last few years, as 
new transplantation and preservation techniques have allowed the 
increased availability of tumor models from different disease areas. 
Their genetic and microenvironment similarity to their disease of 
origin, albeit in the absence of an adaptive immune system, make 
the results obtained from them potentially more translatable than 
those from CDX. As such, PDX models are currently increasingly 
used in “n = 1 mouse PDX trials” to explore genetic/epigenetic/
transcriptome predictors of drug sensitivity for patient selection 
hypotheses.9 Although tumor response end points similar to those 
used in the clinic are derived from these studies, a current gap is 
that quantitative translation has not been demonstrated. Whereas 
widely used to explore targets expressed in/on the cancer cell and 
vasculature, these CDX and PDX models lack any insight into the 
impact of the adaptive and (to varying extents) the innate immune 
system, as these tumors will only grow in immunodeficient animals.
In the era of IO, the need to use immunocompromised mice 
in CDX and PDX models becomes a major barrier to evaluating 
drug-induced tumor shrinkage of IO agents. Alternative mod-
els, such as syngeneic and genetically modified models of cancer, 
may be used when an immune system is required for efficacy. In 
contrast to xenografts, transplantable syngeneic models have been 
far less well-characterized. For standard mouse syngeneic models, 
recent studies have provided additional characterization of the 
genomic, transcriptomic, and tumor microenvironmental land-
scape.10,11 With this increased level of characterization, transplant-
able syngeneic models can be more readily selected to test a specific 
hypothesis. This deeper characterization of the syngeneic models 
provides an opportunity to link therapeutic response to the pheno-
type/genotype of the tumor, providing an opportunity to bridge 
data generated in these models to the clinical setting. Using this 
approach, insights from the syngeneic models can be used to gen-
erate hypotheses about patient selection and identify relevant bio-
markers of response.10
However, there are some limitations associated with trans-
plantable syngeneic tumor models, namely the limited number of 
available models compared with xenografts as well as their rapid 
growth rates (outlined further in Table 1). Genetically engineered 
mouse models (GEMMs) recapitulate the anatomic site of disease 
through use of tissue-specific promotors and can be designed with 
mutations that frequently occur in human disease. GEMMs may, 
therefore, recapitulate the formation of a complex microenviron-
ment shaped by the stochastic interaction of the tumor cells with 
the immune system.12 However, their long latency times and re-
quirement for large breeding colonies limit the throughput of these 
models. Moreover, when compared with chemically induced syn-
geneic transplantable models, GEMMs have a limited mutational 
burden and genetic mosaicism, which may influence the develop-
ment of an antitumor response and, therefore, may not recapitulate 
the clinical setting.13
For all these animal tumor models, it is standard practice to 
measure subcutaneous tumor volume by manual measurement of 
length and width using calipers. A spheroid mathematical formula 
is then used to approximate volume. This method suffers from 
inter-operator and intra-operator variations.14,15 Further, the re-
peatability and accuracy of caliper measurements are negatively 
affected by the morphological complexity of tumors: tumors are 
often irregular, may contain fluid, and are mobile beneath the 
skin.16 Three dimensional scanning provides an opportunity to 
noninvasively derive tumor morphometry, such as length, width, 
area, height, or volume.15 Thermography is used to enhance the lo-
calization of subcutaneous tumors, as xenografts tend to be cooler 
than the surrounding tissue.17 This effect is probably due to the 
tortuous vasculature within the tumor being inefficient at distrib-
uting blood. Furthermore, thermal imaging is, in most instances, 
sufficiently sensitive to detect tumors before they can be palpated 
and can detect changes due to therapy within hours of exposure.17
The frequency of these caliper measures is typically once every 
2–3 days, which is a considerable burden on laboratory resource. 
Parra-Guillen et al.18 demonstrated that reducing the number of 
measurements to twice per week, or even once per week for cell 
lines with low growth rates, showed little impact on model-esti-
mated parameter precision. However, large studies (i.e., > 50) were 
still required to accurately characterize parameter variability. A 
further consideration is that for heterogeneously responding ani-
mal models, reporting, or modeling, the group mean tumor size is 
inappropriate. Analysis of xenograft efficacy data can also be sup-
plemented by considering animal dropout in the studies.19 This is 
particularly important where welfare issues due to tumor burden 
and drug-toxicity can confound the interpretation of data.
Tolerability assessment in animal disease and efficacy models is 
important to evaluate animal welfare and potential confounding 
effects in the interpretation of the studies. Body weight is measured 
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daily (with > 20% body weight loss being judged as intolerable in 
the United Kingdom). This is probably largely indicative of gastro-
intestinal toxicities, which may be shown to be important dose lim-
iting toxicities. General behavioral signs are also monitored (e.g., 
lethargy, posture, and gait changes). Usually, these are observed in 
a small fraction of animals, and their scoring can be idiosyncratic. 
Other more objective external signs, such as redness, ulceration, 
necrosis, and pallor, can be used as biomarkers for animal welfare. 
There are combined visual scanning and artificial intelligence solu-
tions being developed to automatically identify these signs.20 Being 
able to measure cardiovascular end points, including hemody-
namics (e.g., blood pressure) and blood count changes, might also 
enable more informative animal pharmacology studies. However, 
given the size of a mouse, the volume and number of blood sam-
ples that can be obtained is limited, and competes with samples 
for pharmacokinetic (PK) studies, which are arguably more crucial 
to the exposure-response interpretation of an efficacy study. In 
addition, proper assessment of drug safety, and thus of the poten-
tial therapeutic index, is usually done in dedicated, and ultimately 
regulated, healthy animal safety studies, where disease status and 
progression are not a confounder.
TRANSLATABLE EFFICACY END POINTS
Even though both patients and animal models of cancer typ-
ically present with measurable tumor burden, the use of dif-
ferent measurement techniques and end points in each setting 
presents a challenge (see Figure 1). For xenografts, the usual end 
point is the percent of tumor growth inhibition calculated by 
comparing the change in mean tumor size in the control group 
to that observed for the treatment group, and growth delay. 
For clinical tumor growth assessment, there is rarely a placebo- 
controlled or untreated comparison, so a similar analysis 
Table 1 Summary of animal models of cancer available, along with their advantages and disadvantages
Tumor model Advantages Disadvantages
Cell line-derived xenografts • Human origin
• Wide variety of tumor types
• Well characterized for genetics and drug 
response
• Good reproducibility of response
• Inexpensive and high throughput
• Need for an immuno-compromised host
• Homogeneous cell population
• Does not recapitulate the complexity of tumor 
progression
Patient-derived xenografts • Human origin
• Closely resemble the original disease
• Wide and relevant genetic variation
• Can be used to study metastasis and tumor 
genetic evolution
• Need for an immuno-compromised host
• Possible long latency periods and variable 
engraftment rates
• Expensive
Syngeneic • Hosts are immuno-competent
• Some models well-characterized for genetics 
and drug response
• Inexpensive and high throughput
• Not of human origin
• They do not represent the disease of origin
• Few models available
• Tumors tend to grow too fast
Spontaneous 
(e.g., GEMM)
• Hosts are immuno-competent
• Mimic many types of human diseases
• Good to study disease development and 
prevention
• Not of human origin
• Low mutation burden
• Long time to develop disease
• Not all animals get disease
• Variability in disease progression
• High animal numbers needed for breeding 
programs
GEMM, genetically engineered mouse model.
Figure 1 Schematics comparing and contrasting efficacy end points in animal models (left) and in patients (right). [Colour figure can be viewed 
at wileyonlinelibrary.com]
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approach is not possible. Instead, clinical tumor response is 
typically evaluated using the Response Evaluation Criteria in 
Solid Tumors (RECIST)-based objective response rate,21 objec-
tive response rate (ORR) and progression-free survival (PFS). 
In RECIST 1.1, tumor burden is measured as the sum of lon-
gest diameters (SLDs) of up to 5 measurable lesions. ORR is 
calculated as percentage of patients who achieve at least a 30% 
decrease in SLD from baseline at any assessment. PFS is mea-
sured as time to tumor progression, or time to death (whichever 
comes first). Although PFS can be used to support new drug ap-
proval, it is time to death from any cause (a.k.a. overall survival 
(OS)), which is considered the gold standard for drug efficacy. 
For animal welfare reasons, survival is not an end point used 
in nonclinical studies: however, the time to a predefined death 
end point is the closest nonclinical end point comparable to OS.
These nonclinical and clinical end points are often compared 
inappropriately: for example, tumor growth inhibition in an an-
imal model is often directly correlated to clinical ORR, without 
proper PK/PD driven interpretation and without consideration 
of whether the xenograft/ allograft model used was representa-
tive of the clinical population.7 The work of Wong et al.7 and 
Rocchetti et al.,22 as well as Inaba and co-workers23,24 has at 
least demonstrated the potential to predict the clinical efficacy, 
at least as a ranking, of multiple compounds by considering PK 
differences between species as well as potency and clinical toler-
ability. An analysis of the National Cancer Institute nonclinical 
and clinical databases25 is suggestive that broad activity across a 
range of animal cancer model is indicative of activity in patients. 
However, the same analysis did not demonstrate that matching 
histology increased predictivity.
Based upon the above observations in the literature, achieving 
unbound drug exposure26 and biomarker modulation in patients 
similar to those observed in animal studies should be considered 
as necessary (e.g., ref. 27), but not sufficient for observing efficacy 
in the clinic. Obtaining PD data in patients is an opportunity to 
back-translate and build upon nonclinical learning and improve 
translation. The pembrolizumab case study28 illustrates the ben-
efits of such an approach and provides a useful roadmap for the 
challenging case of immunomodulation. However, obtaining tu-
mor-based PD data in patients requires invasive testing, consid-
erable resource, and may ultimately impact patient recruitment to 
clinical trials.
A clinical (and nonclinical) challenge is measuring PD longi-
tudinally in the same subject. Failing to collect longitudinal data 
makes it very difficult to disentangle the various sources of variabil-
ity from the actual PD trajectory. Paired (pre-start and post-start 
of treatment) biopsies are commonly collected in early clinical tri-
als to demonstrate target engagement in tumors and to determine 
whether the necessary pharmacology for efficacy is achievable at 
tolerated doses. The two biopsies will not be from the same lo-
cation of the tumor and, therefore, some variability between the 
samples is driven by variations in the composition of the samples, 
in addition to whether the sample is taken from a primary vs. met-
astatic lesion. The situation is even more challenging in nonclinical 
studies, where, despite the ease of measuring tumor burden longi-
tudinally, only control and treatment groups are compared for PD, 
and there is no internal control for interindividual variability (i.e., 
tumor tissue samples for PD analysis are often collected at termi-
nation only).
Thus, there is the potential for significant inflation of PD vari-
ability estimates. Some laboratories have investigated the use of 
fine-needle aspirates to obtain serial samples for PD from subcu-
taneously implanted tumors in mice.29,30 Although the data are 
encouraging, some spatial variability still confounds full analysis. 
Therefore, further investment in experimental methods that allow 
more nonterminal longitudinal tumor biopsies in animals are 
recommended.
There is also the potential to measure more clinically com-
parable circulating and imaging end points. Indeed, Rago et 
al.31 have reported the measurement of circulating tumor DNA 
in mice as a longitudinal surrogate for tumor burden. Further, 
Mair et al.32 demonstrated that, based upon data from a pa-
tient-derived orthotopic model of glioblastoma, mitochondrial 
DNA has potential as a sensitive endpoint for detecting tumors. 
Imaging of tumor metabolism has been investigated with fluo-
rodeoxyglucose-based positron emission tomography imaging in 
nonclinical and clinical studies33,34 demonstrating this marker 
to be predictive of clinical outcome after chemotherapy, as well 
as with fluorescence imaging.35 Other metabolism-based imag-
ing end points have been investigated in mouse models, includ-
ing labeled pyruvate, fumarate, and lactate,36,37 and shown to be 
predictive of treatment effect. These noninvasive longitudinal 
end points, that can be measured in animal models and patients, 
present the opportunity for more translatable criteria to proceed 
in the clinic.
TRANSLATIONAL CONSIDERATIONS IN PHASE I ONCOLOGY 
TRIALS
All oncology first-in-human (FIH) trials make use of nonclinical 
data in their justification and study design. Aspects of FIH trials, 
which may use these data include:
• The starting dose. This is typically derived from a combination 
of animal safety data and predicted human PKs, derived from 
in vitro and in vivo PK data.38
• The PK sampling scheme. The predicted human PK profile is 
commonly used to plan blood collection time points to opti-
mally evaluate clinical PK. Nonlinearities observed in nonclin-
ical PK studies may be incorporated.
• The planned dose range and dosing frequency. By identifying 
a target efficacious concentration through nonclinical bio-
marker/xenograft studies, this information may be coupled 
with the predicted human PK to project the efficacious dose 
range in humans. This helps evaluate the viability of the can-
didate molecule and helps to plan the dose amounts and dosing 
frequencies, which may be explored in the clinical trial.
• The PD sampling schedule. If a biomarker for target engage-
ment or biological activity is identified preclinically and might 
be relevant/detectable in the clinic, the dynamics of the PD re-
sponse in vivo, which has been characterized preclinically may 
be used to inform PD sample collection time points in the clin-
ical study.
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In seeking an understanding of the potential efficacious dose 
range from nonclinical data, robust translational animal models 
and appropriate PK/PD analysis tools are required. Where solu-
ble or tissue PD biomarkers used in animals can be evaluated in 
patients, exploring the dose range during FIH trials in the clinic be-
comes a highly informed process. However, such biomarkers often 
do not readily exist, so clinical dose exploration is typically limited 
to identifying safe and tolerated doses up to a maximum tolerated 
dose (MTD) level. However, by using a guided approach to dose 
escalation and schedule exploration based on in vivo potencies 
and efficacious drug concentrations identified in animal models, 
the potentially efficacious dose and dosing schedule may be bet-
ter identified ahead of phase II studies. FIH dose escalation plans, 
which incorporate nonclinical predictions of the efficacious dose 
range, should be updated with emerging clinical (and nonclinical) 
safety and/or efficacy data as it emerges to inform dosing regimens 
for testing in subsequent studies.
The approach described above, where predicted exposure-re-
sponse relationships are updated as clinical (and nonclinical) data 
become available, are most powerful when they are actively in-
corporated into FIH study design. Such alternative model-based 
study designs for FIH trials take emerging data and update the 
PK/PD model assumptions and parameters, then use the revised 
predictions to inform the next dose level. One such example of 
model-based study design, the time-to-event continual reassess-
ment method,39 incorporates a time-dependent dose-toxicity 
relationship, which predicts the likelihood of an adverse event. 
Time-to-event continual reassessment method designs provide the 
opportunity for longer dose limiting toxicity windows without ex-
cessive delays in running the study, which may be particularly rel-
evant for radiotherapy studies. Another example of model-based 
study design is the exposure-driven escalation with overdose con-
trol,40 which uses emerging PK information from the ongoing clin-
ical study to update the model and to predict the next dose. In all, 
these designs allow the nonclinical data package to inform clinical 
dose escalation, while also considering human PK/PD data as it 
becomes available. These study designs typically offer a faster path 
to FIH study completion, partly because the Bayesian methodol-
ogy accepts uncertainties associated with small patient data sets. 
Model-based approaches also incorporate data from all cohorts, 
something rule-based approaches generally do not do.
There is ongoing debate as to whether phase I studies are ade-
quately designed for the purposes of the clinical development pro-
gram that will follow. As an example, it is not clear whether current 
rule-based dose escalation designs41 fully characterize the safety and 
tolerability profile of the drug, particularly chronic dose-limiting 
low-grade toxicities. Even the newer designs discussed above may 
fail to predict delayed or chronic toxicities due to the definition of 
the dose limiting toxicity period. This leads to dose interruptions 
and reductions in later clinical development42 that the FIH study 
did not clearly predict. As data emerge from the FIH and phase II 
clinical trials, the use of PK/PD modeling to evaluate the therapeu-
tic window and propose optimized dosing regimens should be used 
during clinical development. This allows any newly proposed doses 
to be assessed prior to registration where possible (e.g., phase II/
III). Making final dose decisions based solely on FIH data can be 
particularly erroneous, as cancer drugs often exhibit large PK and 
biological variability either due to drug characteristics or the use 
of highly heterogeneous patient populations (e.g., multiple tumor 
types) and small patient numbers in typical FIH study designs. 
In addition, as oncology FIH studies become more complex and 
potentially continue through to registration (e.g., via a multi-arm 
multistage study), such re-evaluation of the optimal dose and dos-
ing regimen should be actively considered.
Historically, FIH studies have prioritized safety and MTD find-
ing as the primary objective(s), with PK, immunogenicity (for bio-
logics), and PDs being either secondary or exploratory objectives. 
However, the MTD approach does not necessarily best inform the 
recommended phase II dose.43,44 This is particularly relevant for 
highly selective drugs (e.g., monoclonal antibodies), which elicit 
maximal effect at sub-MTD doses.45 As drugs become highly 
targeted, PK and PD end points and combined PK/PD analyses 
should take greater prominence in FIH design and recommended 
phase II dose identification. Furthermore, cancer drugs are com-
monly used in combination with other novel drugs or standard 
of care therapies, and many studies now incorporate both single 
agent and combination arms, so PK and PD can be characterized 
in parallel. In these complex cases, PK/PD evaluation can (as study 
design allows) be used to identify and quantify the individual con-
tributions of each combination drug to the observed combination 
therapy safety/efficacy profile, and thus optimize the combination 
dose to achieve the best possible benefit/risk ratio.
TRANSLATIONAL CONSIDERATIONS IN PHASE II AND 
PHASE III
Regulatory agencies consider OS as the most reliable and, if fea-
sible, the preferred end point for oncology trials.46 However, for 
cancer indications with median survival times >  1  year, relying 
solely on OS for drug approval can significantly delay the availabil-
ity of treatments to patients. In lieu of OS, regulators frequently 
accept PFS, and occasionally ORR, as end points for accelerated 
approval pathways and registration. Furthermore, whereas OS is 
an unambiguous, precisely measured end point, its relationship 
to the study treatment under consideration can be confounded by 
the subsequent treatment sequence. A key challenge, therefore, is 
the prediction of OS from early indicators of drug activity, such 
as change in disease burden as assessed by RECIST criteria.47,48 
Early indicators of activity, such as change in SLDs at 8  weeks, 
may indicate extent, but not duration, of response.49 Such work is 
useful to provide an early assessment of drug viability50,51; but typ-
ically cannot be used to support drug registration. An interesting 
model-based observation52 is the potential discordancy between 
initial rate of tumor shrinkage and the duration of response. 
Further, after progressing on an early line of treatment, a patient is 
often switched to a different treatment, which will hopefully im-
prove their OS. It is likely that each line of treatment impacts the 
composition of progressing tumors53 in a drug target-specific and 
mechanism-specific way, probably resulting in increasing with-
in-patient and between-patient disease heterogeneity as treatment 
proceeds. Indeed, in some trials where the study drug becomes 
an approved treatment option, it is possible that some patients 
who were randomized to receive placebo may later receive study 
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treatment. Statistical methods have been proposed to derive un-
biased estimates of treatment effect in the presence of treatment 
switching.54 It should also be recalled that phase I trials usually 
recruit patients with late-stage disease with a range of different 
tumor types. Clearly, the development of predictive early efficacy 
end points and modeling techniques is an area requiring ongoing 
modeling research. Of note is that for IO treatments a revised as-
sessment criterion, iRECIST,55 has been developed to account for 
differences in the initial response of tumors to those treatments.
In later phase trials, modeling of clinical efficacy data concen-
trates on SLD, PFS, and OS where available. When modeling 
tumor dynamics, researchers should be aware of the information 
that may be gained by using the spectrum of currently available and 
emerging radiographic features instead of reducing the richness of 
the imaging data to just SLD. These features include the following:
a individual lesion diameters (ILDs) and their response to 
treatment
b lesion location
c lesion volume
d lesion morphology
e nontarget lesion data and appearance of new lesions
An example of currently available feature is ILD and modeling 
data sets should include these wherever possible. If an exploratory 
analysis reveals divergent or mixed responses between individual 
lesion within subjects, researchers should consider modeling ILDs 
rather than SLDs. Such an analysis can be achieved using a nested 
hierarchical model, such as a mixed effects approach.56,57 There 
can be significant correlation between ILDs within a patient,58 
possibly driven by PK and common genetics, however, they are not 
perfectly correlated. The impact of dropout, compliance, and the 
existence of patient subpopulations, for example, via statistical mix-
ture modeling, should also be explored. Promising efforts are under 
way to combine qualitative longitudinal data on nontarget lesions 
and new lesions with target lesion data to improve outcome pre-
dictions.59 Moreover, incorporating biomarker responses in tumor 
kinetic modeling has the potential to resolve the pharmacological 
variability of different response types in order to better predict the 
duration of response.60 Despite some progress, longitudinal tumor 
size models tend to be agnostic of mechanism of action (MoA).61,62 
Careful review of the dynamic features of nonclinical data accom-
panied by MoA-based hypothesis generation and model-based hy-
pothesis validation can help identify mechanistic model features 
in nonclinical data, which may be hard to establish in clinical data 
due to small subject numbers and limitations of clinical practice. 
To this end, in vitro data on pazopanib’s anti-angiogenic and cyto-
toxic effects together with dynamic features in mouse in vivo data 
guided the development of a semimechanistic model, including 
both MoAs, which resulted in improved characterization of both 
in vivo and clinical tumor size data.63 Another opportunity to in-
form more mechanistic clinical tumor size models is provided by 
applying nonclinical mathematical models linking PD biomarker 
changes to tumor response8,64 to clinical data.
A second challenge for oncology clinical development are the 
complexities arising from the need to combine an experimental 
treatment with the current standard of care as a “back bone” treat-
ment65 or with another experimental treatment to increase the 
pool of responding patients. With many novel-novel combinations 
available, nonclinical experiments and translational modeling play 
an important role to guide clinical development by: (1) prioritiz-
ing the choice of combination partner and the degree of synergy 
by in vivo efficacy ranking27; (2) assessing whether concurrent 
administration or specific sequencing is more promising or worth 
exploring64,66; and (3) characterizing the in vivo PD response to 
guide combination biomarker strategy and starting dose selec-
tion.67 There are few examples of clinical trials that go on to test 
optimal sequencing of treatments, although one notable example is 
the GeparNuevo trial combining an immune checkpoint inhibitor 
with chemotherapy.68
Third, there are challenges to applying PK/PD and other dose/
exposure analyses in oncology. Partly, this is due to the impact dis-
ease can have on PK and so “PD feeds back on PK,” as has been 
shown for checkpoint inhibitors.69,70 Here, disease state variables 
with prognostic potential can impact drug exposure, and thus can 
act as confounders for exposure-response analyses. There are also 
the issues of adherence, dose interruptions, and dose reductions, 
that might confound standard exposure response analyses. This 
makes interpreting efficacy and safety end points challenging. A 
good example of this71 was the abemaciclib MONARCH 2 trial, 
where OS curves stratified by drug exposure on day 15 of treat-
ment suggested that patients with the lowest exposure fared better. 
However, this is likely to be an artifact introduced by dose interrup-
tions and reductions seen predominantly for patients with greater 
than average drug exposure. Indeed, for monoclonal antibodies 
whose PK depends on target expression, time-varying changes in 
drug clearance are often related to response, such as for avelumab 
where the magnitude of reduction in drug clearance over time 
was higher in responders compared with nonresponders.72 
Another challenge to exploring full exposure-response in oncology 
is that exposing patients with cancer to doses that are predicted to 
be ineffective (as would be expected in a full dose-response charac-
terization) raises ethical questions and many of the newer FIH trial 
designs minimize the number of patients treated in such low-dose 
cohorts.
Radiotherapy is an example where translatable nonclinical data 
(in vitro) informs the treatment of patients. This includes the opti-
mization of dosing schedules when incorporated into mechanistic 
mathematical models of tumor response.73 The Linear-Quadratic 
(LQ) model74 works well in its domain of applicability: radiation 
doses of 1–8 Gray. A knowledge of the cumulative on-target ef-
fect of radiation, toxicities in neighboring healthy tissues, and the 
potential for tumor recovery during treatment holidays has led to 
a quantitative framework to guide patient treatment: parameters 
for the LQ model from in vitro studies with cell lines relevant to a 
patient’s disease are used as part of this. The effectiveness of these 
approaches is backed up by prospective trial results.75 However, the 
LQ model may not be appropriate for some of the hypofraction-
ated high-dose regimens that are being tested now.76 Therefore, an 
updated model is required to broaden the domain that this model 
framework can be applied to. Park et al.76 proposed a “universal” 
survival model, combining the LQ equation for low dose and the 
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multitarget model for high dose. Below a certain cut-off dose, the 
LQ equation is used; whereas above this dose, the multitarget 
model was suggested.
An interesting development is the use of image-guided radiation, 
including the use of image density as a surrogate of cellularity. This 
is used with the hope of concentrating the dose where the tumor 
cells are most prevalent. This touches on the application of radio-
mics77 to provide surrogates of biological processes that might aid 
diagnosis and treatment decisions as well as provide useful mech-
anistic information for modeling approaches. As part of the deep 
learning revolution in imaging, new feature extraction methods are 
arising, potentiating the extraction of biomarkers from images and 
their multifaceted analysis.78
MATHEMATICAL MODELING APPROACHES TO 
TRANSLATION IN ONCOLOGY
For systemic therapies used to treat animal models, several math-
ematical modeling approaches have been applied. The most 
commonly adopted models focus primarily on drug effects in 
a nonspatially resolved framework of coupled equations with 
tumor mass given as a growth law. The models for mass growth 
vary greatly, ranging from simple exponential8 to more complex 
models,79 including models based on tumor surface growth.80 
However, distinguishing between growth laws is challenging, 
given the available data.81 In practice, the utility of the model-
ing has been largely to formally derive a concentration-effect re-
lationship,82 but also to investigate drug MoA, scheduling, and 
combinations (e.g., ref. 64 by incorporating biomarkers of target 
engagement and/or biological response. The end-goal of the model 
then is focused on establishing these longitudinal biomarkers as 
predictors of tumor response, and their relationships to dose and/
or concentration. These relationships are then used to set target 
concentrations (and so doses) that support taking a new molecular 
entity into the clinic as well as setting PK, PD, and tumor kinetic 
criteria for progression into phase II trials. The rationale for this is 
that biomarker modulation enhances and augments the predictive 
power of changes in tumor mass.60
The tumor size data from image-guided radiation systems pro-
vide near daily measurements of tumor size: something that is 
not seen in trials of systemic therapies. This provides informative 
data83 that allows the initial response and growth of tumors to be 
modeled mathematically in detail. Further mathematical modeling 
studies84 have incorporated tumor composition and spatial detail 
to explain delayed treatment responses. However, when consid-
ering clinical data, such full spatial model parameterizations are 
typically unfeasible with the temporal resolution of the data only 
allowing a concentration or dose dependency to be determined 
from the model. As a result, Lewin84 also developed a simpler two 
compartment ordinary differential equation-based model to de-
scribe tumor dynamics as a result of radiotherapy, which could be 
used for the type of tumor size data typically collected in the clinic.
As discussed earlier, translation of nonclinical responses to clin-
ical outcome and drug registration is highly challenging. One po-
tential solution is to incorporate additional mechanistic descriptors 
in the modeling framework to describe differences between animal 
models and the clinic and so potentially improve translation, such 
as proliferating fraction, cell cycle time, and drug-resistant cells. 
Most models used in drug R&D programs are not spatially re-
solved, despite there being clear evidence that the spatial structure 
of tumors will considerably affect tumor response to treatment.85,86 
This contrasts with the academic literature on tumor modeling 
where spatially resolved models have been developed.87 Spatial 
effects of clear relevance to predicting patient response include 
potential structural and genetic heterogeneity within tumors. 
Considering drug concentration gradients in tumors, stromal ar-
chitecture can affect drug availability by several orders of magni-
tude85 and can drive drug-resistant clonal selection.88 Modeling 
approaches could encompass detailed tumor simulations of drug 
availability89 through to classification-based approaches where ar-
chitecture can be used to predict responsiveness.90 However, the 
within-patient tumor physical and mechanical environment influ-
ences PD effects,91,92 with recent results showing efficacy across a 
range of cell lines and therapeutics being affected by environmental 
stiffness.93 Using modeling to encompass the range of confounding 
effects would involve substantial complexity but with the potential 
to improve translational efficacy, for example, to account for the 
different sensitivities of tumors in different anatomic locations. 
A recent example of the application of mechanistic modeling to 
understand drug distribution effects is that for antibody-drug con-
jugates94 where antibody and drug PK are integrated alongside the 
expression and internalization of the target cell surface receptor.
An important new and developing modeling application is 
that of tumor-immune interactions, with currently few examples 
developed with direct pharmaceutical applications, despite this 
class of therapy becoming increasingly important. There are, how-
ever, new models being developed that capture tumor-immune 
interaction in a mouse syngeneic tumor allowing combinations 
of radiation and immune checkpoint inhibitors to be modeled.95 
A second example of the application of mechanistic modeling to 
IO is the quantitative modeling of chimeric antigen receptor T 
cell therapies.96,97 Agent-based and individual-based simulations 
are increasingly used for this application, with these simulations 
being, of course, spatially resolved in their outputs.98 This does, 
of course, increase their computational cost. This should be an 
area where the community revisits existing models proposed in 
mathematical immunology, in the current context of increased 
availability of data to inform these models (e.g., ref. 99). These 
(mostly differential equations-based) models, despite having been 
proposed some time ago, can still be used to describe complex im-
munological mechanisms, such as polyclonal responses, in a less 
computationally costly framework.
DISCUSSION: OPPORTUNITIES FOR TRANSLATIONAL 
ONCOLOGY
It is clear that there are several opportunities that should be ex-
plored to further the application of quantitative techniques in on-
cology, not least because oncology has the largest body of literature 
on mathematical modeling.100 It is becoming clear that in vivo 
to clinical translation is not the only challenge: prediction from 
one phase of clinical trials to another is still difficult. A key issue 
for the field is the lack of connection between modeling efforts: 
preclinically to clinically; statistical to mechanistic.101 Below is 
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a summary of key opportunities, reported in their approximate 
chronological order in a drug R&D program progression process.
There are significant gaps in the literature in evaluating the 
predictivity and reproducibility of animal cancer models. Many 
studies consider relatively small data sets or are deficient be-
cause they do not correct for such things as the differences in 
free drug exposure achieved in the mouse vs. patients. This can 
result in animal experiments that cannot be replicated, an issue 
compounded by the poor reporting of basic experimental pa-
rameters, such as animal numbers and randomization.102 This 
gap could be filled via a precompetitive exercise to look at repro-
ducibility between laboratories of in vivo cancer models: does 
the “same” animal model grow the same way and show the same 
concentration-response relationship across laboratories? If not, 
then translation from a handful of models in one laboratory is 
a forlorn hope.
Following from this comes the idea of “cohorts of biological 
models”: using multiple animal cancer models to fully elucidate 
mechanism of action of direct tumor targeting vs. immune ef-
fects and pre-empt potential heterogeneity in clinical response. 
Stressing the therapeutic index hypothesis fully in a range of non-
clinical models might reduce the impact of false-positive findings 
from nonclinical research and guide the indication selection for 
early clinical development. There is some evidence that generating 
a more heterogenous nonclinical data set will improve the robust-
ness and reproducibility of results.103 How the range is chosen (cell 
lines or PDX models) would depend on the specific question at 
hand. Importantly, all the models selected should be included in 
an integrated quantitative modeling framework, and bias toward 
just those animal models that provide a positive signal should be 
avoided.
Although research organizations use nonclinical data and 
modeling to inform early clinical studies, the question of quan-
titative translation remains open. One clear opportunity is to 
translate the mechanistic learning from in vivo models to the 
clinic by applying mathematical models that reflect the drug 
MoA. The need, therefore, exists for simple mechanistic models 
that can be applied to animal and clinical data to allow direct 
comparison. Several reports on the performance of a broad range 
of existing models for tumor growth trajectory81 point to there 
being no clear differences in explanatory power when applied 
to nonclinical data. However, few of these models mechanisti-
cally describe the key physical processes of tumor growth and 
response to treatment and, therefore, what the key differences 
between animal models and the human disease might be. Thus, 
models that incorporate biomarker modulation and its impact 
on tumor growth inhibition104 would be preferable, especially 
because these mechanistic aspects would, in principle, translate 
better than simple tumor mass growth patterns. It is also clear 
that further work needs to be done to develop mathematical 
models that incorporate aspects of the immune system and its 
interaction with tumors.
Current phase I study designs and data analysis approaches do 
not always fully characterize the frequency and severity of adverse 
events observed in the wider patient population,42 mainly due to 
logistical challenges in the design and execution of these trials. 
This leads to dose interruptions, reductions, and withdrawal of 
patients from subsequent trials, all of which can severely con-
found the analysis of exposure response in phase II to further 
optimize regimen. Therefore, further research in trial design and 
data analysis is needed into generating a more adequate charac-
terization of drug-dependent efficacy profiles and adverse events.
Further exploration is required of new sources of clinical and 
nonclinical in vivo data that could help parameterize models: 
greater use of computed tomography scan data, such as radiomic 
approaches, to inform on the physical structure of tumor lesions 
and development and validation of one-dimensional quantitative 
measures of spatial characteristics, which can be integrated in clin-
ical modeling approaches; circulating biomarkers, such as tumor 
antigens (including PSA and CA125), circulating tumor cells and 
circulating free tumor DNA; imaging mass-spectrometry data to 
give spatial resolution on drug and biomarker distribution in tumor 
tissue.105 Data sharing through public databases (e.g., Project Data 
Sphere and Vol-PACT: https://fnih.org/what-we-do/biomark-
ers-consortium/programs/vol-pact) and precompetitive industrial 
collaborations could facilitate this.
Such mechanistic models should contain some of the more 
spatially relevant effects discussed in preceding sections, as well 
as potential intra-tumor and inter-tumor heterogeneity that 
would be predictive of patient response rate and emergence of 
therapy-resistant disease. However, when considering the devel-
opment of more mechanistic models, the complexity of a model 
needs to be tailored to the level and richness of data available 
from clinical studies.
Another opportunity for a more mechanistic approach to 
modeling clinical data would be the ability to integrate appar-
ently disparate clinical trial data sets by reflecting differences/
commonalities via the model parameterization. This can now be 
done, for example, in pharmacometric analyses of clinical data, 
where PK and efficacy information from several clinical trials is 
pooled in a single analysis and the underlying model is shared 
across all datasets.28 If extended to other cancers or treatments, 
this kind of analysis could bring a more global understanding of 
the disease course of a cancer, the response to different therapies, 
and how previous therapies impact the response to subsequent 
therapies, including evolutionary pressures and how different 
therapies result in the emergence of resistant clones. Similarly, 
MoA-based models would enable comparison of the effect for a 
drug or combination of drugs across a wide range of cancers, with 
the assumption that the MoA is conserved but the sensitivity to 
treatment might vary between cancers. Such models might enable 
a more refined prediction for new drugs with an MoA related to 
an existing therapy. The data sources to inform such models is 
likely to be a synergy of nonclinical and clinical information.
A final opportunity for such a consistent, MoA-driven modeling 
approach is the optimization of dosing schedules in combinations, 
including gaps and sequences. Combination treatments can be ex-
plored in some level of detail in a nonclinical setting, and so reap-
plying the model in the clinic with minimal recalibration (purely 
simulating existing, sparse measurements, instead of refitting the 
models) allows knowledge to be quantitatively transferred and the 
nonclinical hypothesis to be formally tested against clinical data. 
WHITE PAPER
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 108 NUMBER 3 | September 2020 455
The failure of such a test would nevertheless be informative. With 
a refined understanding of the effects of existing treatments, as dis-
cussed in the previous paragraphs, combination effects might be 
predicted and optimized computationally, by combining mechanis-
tic models of monotherapy.106 However, one clear barrier to the full 
application of modeling and simulation to combination regimen 
optimization is given by the objective obstacles to altering the regi-
men for standard of care or advanced stage experimental medicines.
Clearly, in conclusion, mathematical modeling approaches have 
impacted translation in oncology drug research and development. 
Coupled with more sophisticated nonclinical biological models of 
cancer and a growing range of measurement techniques, these have 
enabled more informed decision making. In this report, we have 
surveyed the existing state of the art, the challenges of translation, 
and identified where there are further opportunities to make gains 
in more efficient drug research.
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